give me 10 objective for this :
Introduction :
Statins are known as safe and efficient therapy for arteriosclerotic cardiovascular disease (CVD). Statins include additional health advantages beyond their primary role of reducing cholesterol levels. This broad spectrum of efficacy has recently gained a lot of attention, establishing statins as a prospective therapy choice for a variety of disorders other than lipid profile stabilization and cardiovascular disease prevention.
In addition to their beneficial impact on vascular health, many studies have identified the potential pleiotropic effects of statins that may influence various tissues and organs. Statins have been observed to exert a pleiotropic effect on oral health . Apart from its effectiveness in controlling cholesterol levels, it also has anti-inflammatory, immunomodulatory, and antioxidant effects [1]
Dyslipidemia is a significant risk factor for cardiovascular disease, and cholesterol-modifying medication has proven advantages in the primary and secondary prevention of coronary heart disease and stroke. Lipid-lowering agents, particularly HMG-CoA reductase inhibitors (statins), have emerged as a cornerstone in therapeutic protocols for managing these conditions [2, 3].
Statins largely lower LDL levels by blocking the HMG-CoA-reductase enzyme, which is responsible for the earliest important step in the mevalonate pathway involved in cholesterol formation. 
Statins are suggested for patients with stroke or TIA with co-morbid CHD to attain a target LDL goal of < 100 mg/dL and LDL < 70 mg/dL for very high-risk persons with several risk factors.
In patients with stroke or TIA who do not have concurrent CHD or hyperlipidemia, starting statin therapy is deemed appropriate for the prevention of future CVD events. [4].
Currently, coronary heart disease (CHD) is the leading cause of mortality in most countries, largely attributable to the concurrent epidemics of obesity and diabetes.[5]. Statins are the hypolipidemic treatment of choice for hyperlipidemia with a confirmed atherosclerotic cardiovascular disease (ASCVD) protective effect, proven even in norm lipemic patients [6]. 
literature review:
In the ASCOT LAA primary prevention study of high-risk patients receiving treatment, saw a decrease of 27%, while in the JUPITER primary prevention trial among low-risk patients, there was a reduction of 51% in ischemic stroke incidence linked to statin therapy. [7]
study involving 4,444 patients with confirmed CHD, prolonged administration of simvastatin was shown to considerably decrease mortality rates by 30% and coronary events by 34%. [8]
Additionally, modest, non-randomized investigations indicated that statin medication was associated with considerable improvements in walk performance and general leg function in patients with PVD. [9,10]
The effectiveness of statin therapy in the primary prevention of CVD in patients with diabetes was subsequently established by the Collaborative Atorvastatin Diabetes Study (CARDS).[11]
Patients with moderate chronic kidney disease CKD were shown to have nearly 50% higher risk of CVD events compared to those with normal renal function or mild CKD. In a detailed subgroup analysis of the MEGA study, a significant reduction in the occurrences of CHD by 48%, strokes by 73%, and mortality by 51% was observed with pravastatin treatment in individuals with moderate CKD.[12]
Statins may have greater protective effects against MDD and schizophrenia and significant positive effects in the treatment of anxiety disorders without serious adverse side effects. [13]
Statin therapy is associated with a 26% decreased risk of cancer-specific survival and a 24% decreased risk of progression-free survival for advanced-stage cancer patients.[14]
Statins  contribute to alleviating the impact of various eye conditions such as dry eye, corneal ulcer scarring, thyroid-associated orbitopathy, glaucoma, uveitis, and other related ocular inflammatory states, as well as cataract, proliferative vitreoretinopathy, diabetic retinopathy, macular degeneration, and choroidal melanoma. [15]

Over the years, it has been shown that statins reduce the production of numerous proinflammatory cytokines and inhibit the recruitment of monocytes, thereby altering inflammatory cascades and positively affecting the periodontium. [16,17]

Previous research has identified knowledge gaps among physicians and/or pharmacists regarding cholesterol management guidelines and/or CVD risk assessment prior to statin therapy beginning [18-21]. Guidelines include considerable knowledge gaps, particularly in terms of ASCVD risk assessment and statin prescription therapeutic reasons, according to two US surveys of healthcare professionals [22] and professional clinical pharmacists [23]. 
A study in China found that both the degree of comprehension of the national lipid guideline and the management of dyslipidemia among community physicians working in primary care were inadequate. [24]
Aim:
To assess the general knowledge of medical students regarding the different beneficial effects of statins
Objective :
1.	To assess the knowledge of medical students about the cardiovascular protective effects of statins, including their role in reducing the risk of heart attacks and strokes.
2.	To evaluate the understanding of medical students regarding the lipid-lowering benefits of statins, specifically their effect on lowering LDL cholesterol levels.
3.	To assess the knowledge of medical students about the role of statins in reducing cardiovascular complications in patients with diabetes mellitus and obesity.